MedTrace Logo

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

NCT02838589 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-02-07

No results posted yet for this study

Summary

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist on cerebral blood flow velocity and cortical oxygination in humans without cerebrovascular disease. This study serves as a control for a similar study investigating the effect in stroke patients (ref. to EGRABIS1).

Conditions

Interventions

DRUG

Byetta

Single dose of subcutaneous injection of 5 μg exenatide (Byetta).

DRUG

Isotonic saline

Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).

Sponsors & Collaborators

  • Christina Kruuse

    lead OTHER

Principal Investigators

  • Christina R Kruuse, MD, PhD · Consultant Neurologist, Dept Neurology, Herlev Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02838589 on ClinicalTrials.gov